Immix Biopharma, Inc.
 | |
| ImmixBio | |
| Traded as | NASDAQ: IMMX |
| ISIN | 🆔 |
| Industry | Biotechnology, Biopharmaceuticals |
| Founded 📆 | 2012 |
| Founder 👔 | Ilya Rachman |
Area served 🗺️ | |
Key people | Ilya Rachman, Gabriel Morris, Michael Grabow |
| Products 📟 | NXC-201 |
| Members | |
Number of employees | Approximately 60 |
| 🌐 Website | immixbio |
| 📇 Address | 11400 West Olympic Boulevard, Suite 200, Los Angeles, CA 90064 |
| 📞 telephone | |
Immix Biopharma, Inc., also known as ImmixBio, is an American clinical-stage biopharmaceutical company focused on developing cell therapies and other immune-based treatments for rare diseases.[1] Founded in 2012 by physician-scientist Ilya Rachman, MD, PhD, the company is headquartered in Los Angeles, California.[2] Its common stock is publicly traded on the Nasdaq Capital Market under the ticker symbol IMMX.
Immix Biopharma's principal clinical programme is NXC-201, a BCMA-targeted chimeric antigen receptor T-cell therapy being investigated for relapsed or refractory light-chain amyloidosis, commonly referred to as AL amyloidosis.[3] The company's broader mission is to use the immune system through innovative cell therapies and other modalities to develop accessible treatments for autoimmune diseases and other serious indications.
History
Founding
Immix Biopharma was established in 2012 by Ilya Rachman, MD, PhD, a physician-scientist with a background in clinical medicine, neuroendocrinology, experimental oncology and pharmaceutical clinical research.[4]
Rachman developed an interest in therapeutic development after treating thousands of patients and frequently encountering situations where no further treatment options were available.[5] He subsequently pursued business training at the University of California, Los Angeles, and established Immix Biopharma with the aim of translating scientific research into new therapeutic options for patients.
In its early years, the company developed and tested an initial drug candidate, raised capital from private investors and later completed an initial public offering. Its early research was mainly associated with oncology and the application of academic discoveries to potential cancer treatments.
Expansion into cell therapy
After its public listing, Immix Biopharma began exploring whether advanced cell therapies traditionally used in cancer treatment could also be applied to diseases beyond conventional oncology.
In 2022, the company initiated a systematic search for cell-therapy assets and licensed global intellectual-property rights relating to NXC-201 from Hadassah in Israel. The programme subsequently became the company's principal clinical-stage asset.
This strategic transition directed Immix Biopharma towards developing CAR-T cell therapy for AL amyloidosis, a rare systemic disease in which abnormal plasma cells produce toxic light chains that can accumulate in organs, including the heart, kidneys and liver.
NXC-201
NXC-201 is an investigational, BCMA-targeted chimeric antigen receptor T-cell therapy being developed by Immix Biopharma for relapsed or refractory AL amyloidosis.[6]
NXC-201 is described as a sterically optimised CAR-T therapy incorporating a proprietary CD3ζ signalling domain, CD8 hinge and binder-based "digital filter".[7] Its design aims to reduce non-specific activation while allowing engineered T cells to recognise and eliminate the plasma cells responsible for producing toxic light chains.
NXC-201 targets B-cell maturation antigen (BCMA), which is expressed on plasma cells. The programme represents Immix Biopharma's effort to extend the potential application of BCMA-directed CAR-T therapy beyond conventional oncology into AL amyloidosis.
NXC-201 remains investigational and has not been approved for commercial use.
AL amyloidosis
AL amyloidosis is a rare disorder caused by abnormal plasma cells that produce misfolded immunoglobulin light chains. These proteins can accumulate in organs and tissues, potentially causing progressive damage to the heart, kidneys, liver and other organs.
Immix Biopharma's development strategy focuses on targeting the abnormal plasma cells responsible for producing the disease-causing light chains rather than treating only the resulting organ damage.
Historically, treatment options specifically approved for AL amyloidosis have been limited, creating a need for additional therapeutic approaches.
Clinical development
NEXICART-1
NXC-201 was initially evaluated outside the United States through the NEXICART-1 clinical study.
The NEXICART-1 programme reported a 75% complete response rate in the relevant AL amyloidosis patient population.[8] Clinical findings related to NXC-201 were subsequently discussed in medical literature and presented at scientific and professional forums.[9]
NEXICART-2
Immix Biopharma is evaluating NXC-201 in the United States through NEXICART-2, a multicentre study involving patients with relapsed or refractory AL amyloidosis.[10]
The trial is registered as NCT06097832 and has a potentially registrational design. Its development strategy could support a future regulatory submission if the necessary clinical and regulatory standards are met.
Initial programme results have been discussed in oncology and hematology publications, scientific-video platforms and professional meetings, including materials associated with the American Society of Clinical Oncology and the American Society of Hematology.
Regulatory designations
NXC-201 has received several regulatory designations relating to its development for AL amyloidosis, including:
- Breakthrough Therapy Designation from the United States Food and Drug Administration (FDA);
- Regenerative Medicine Advanced Therapy designation from the FDA;
- Orphan Drug Designation from the FDA; and
- Orphan Drug Designation in the European Union from the European Medicines Agency.
These designations support the development and regulatory review of treatments for serious or rare conditions. However, they do not constitute marketing approval or establish that a therapy is safe or effective.
Research and development milestones
2022
- Initiated and completed a systematic search for advanced cell-therapy programmes.
- Licensed global intellectual-property rights relating to NXC-201 from Hadassah in Israel.
2023–2024
- Secured orphan-drug and other FDA regulatory designations.
- Continued the ex-United States NEXICART-1 programme.
- Reported a 75% complete response rate.
- Received recognition in medical literature addressing AL amyloidosis.
2025
- Published clinical research in the Journal of Clinical Oncology.
- Delivered an oral presentation at the American Society of Clinical Oncology annual meeting.
- Presented clinical data at the American Society of Hematology annual meeting.
- Appointed a Chief Commercial Officer as part of preparations for later-stage development and potential commercialisation.
2026
- Received FDA Breakthrough Therapy Designation for NXC-201.
A potential biologics license application and future commercial launch have been identified as prospective development objectives. These remain forward-looking plans.
Leadership
Ilya Rachman
Ilya M. Rachman, MD, PhD, is the founder, Chairman and Chief Executive Officer of Immix Biopharma. He has served as Chairman and CEO since the company's founding in 2012 and became Chief Scientific Officer in March 2026.
Rachman received a Bachelor of Science degree from the University of Iowa, a joint MD/PhD degree from the University of Illinois Chicago and an Executive MBA from the University of California, Los Angeles. His doctoral research focused on neuroendocrinology.
Before establishing Immix Biopharma, Rachman worked as a physician-scientist at Cedars-Sinai Medical Center and UCLA Health. He also founded a clinical research organisation that conducted Phase III and Phase IV studies involving drugs developed by large pharmaceutical companies.
Ilya Rachman is a physician-scientist and cell biologist who oversees Immix Biopharma's corporate direction and scientific mission. He is also listed as an inventor on several Immix-related patents.
Gabriel Morris
Gabriel Morris is President, Chief Financial Officer and a director of Immix Biopharma.[11] He has served as CFO and director since March 2021 and as President since March 2026.
Morris invested in Immix Biopharma before its initial public offering after meeting Rachman in 2020. He subsequently joined the company to oversee finance, corporate development, business development, investor relations, forecasting, budgeting and company operations.
Morris received a Bachelor of Arts in economics from Columbia University in the City of New York in 2008, having also attended Vanderbilt University as a Vanderbilt University College Scholar. As an undergraduate, he participated in the Icahn School of Medicine at Mount Sinai Humanities and Medicine programme and conducted experimental scientific research.
From 2008 to 2018, Morris worked on cross-border mergers and acquisitions at Goldman Sachs & Co. and other global investment banks. He participated in more than $50 billion in completed transactions.
From 2019 to 2020, he served as interim Chief Financial Officer of Zap Surgical Systems, where he completed an $81 million growth-equity financing. In 2020, he founded Alwaysraise LLC, a life-sciences investment and advisory firm.
Gabriel Morris also co-founded Nexcella, Inc., which was involved in the licensing and development pathway associated with NXC-201. He led Immix Biopharma's IPO and subsequent financing transactions totalling more than $250 million.
Michael Grabow
Michael Grabow serves as Chief Commercial Officer of Immix Biopharma. His appointment was part of the company's preparations for later-stage clinical development and potential commercialisation.
External links
- Immix Biopharma official website
- Immix Biopharma on LinkedIn
- Immix Biopharma on Facebook
- Immix Biopharma on X
References
- ↑ https://www.edisongroup.com/equity/immix-biopharma/
- ↑ https://www.sec.gov/Archives/edgar/data/1873835/000149315221022940/forms-1.htm
- ↑ https://consultqd.clevelandclinic.org/first-ever-us-trial-of-car-t-cell-therapy-for-relapsedrefractory-al-amyloidosis
- ↑ https://scholar.google.com/citations?user=9NaulC8AAAAJ&hl=en
- ↑ https://www.youtube.com/watch?v=_b-4UcAoH9c
- ↑ https://www.mskcc.org/news/car-cell-therapy-for-light-chain-al-amyloidosis-achieves-strong-results
- ↑ https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7508
- ↑ https://ashpublications.org/blood/article/146/Supplement%201/696/554962/First-20-patient-safety-and-efficacy-data-from
- ↑ https://ascopost.com/news/june-2025/early-results-for-car-t-cell-therapy-for-relapsed-or-refractory-al-amyloidosis/
- ↑ https://www.vjhemonc.com/video/ofthc2v8em0-initial-results-from-the-nexicart-2-trial-of-bcma-directed-car-t-nxc-201-in-rr-al-amyloidosis/
- ↑ https://www.prnewswire.com/news-releases/immixbio-announces-gabriel-morris-as-chief-financial-officer-and-a-member-of-the-board-of-directors-301325650.html
